LGND Stock Overview
A biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 1/6 |
Past Performance | 3/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Rewards
Risk Analysis
Ligand Pharmaceuticals Incorporated Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$82.70 |
52 Week High | US$94.57 |
52 Week Low | US$49.24 |
Beta | 0.92 |
11 Month Change | -1.08% |
3 Month Change | 6.08% |
1 Year Change | 18.74% |
33 Year Change | -36.09% |
5 Year Change | -28.74% |
Change since IPO | 37.83% |
Recent News & Updates
Should You Be Adding Ligand Pharmaceuticals (NASDAQ:LGND) To Your Watchlist Today?
Jun 29Subdued Growth No Barrier To Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) With Shares Advancing 27%
May 23Recent updates
Should You Be Adding Ligand Pharmaceuticals (NASDAQ:LGND) To Your Watchlist Today?
Jun 29Subdued Growth No Barrier To Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) With Shares Advancing 27%
May 23Ligand: Buy This Pharma Royalty Aggregator To Generate Growth In Your Portfolio
Apr 30Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Not Flying Under The Radar
Dec 19Is Now The Time To Put Ligand Pharmaceuticals (NASDAQ:LGND) On Your Watchlist?
Jun 14We Think Ligand Pharmaceuticals (NASDAQ:LGND) Can Stay On Top Of Its Debt
May 29Are Investors Undervaluing Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) By 45%?
May 07These 4 Measures Indicate That Ligand Pharmaceuticals (NASDAQ:LGND) Is Using Debt Reasonably Well
Jan 26We Think Ligand Pharmaceuticals (NASDAQ:LGND) Can Stay On Top Of Its Debt
Oct 21Ligand Pharmaceuticals: Struggling Along
Sep 25Growth Investors: Industry Analysts Just Upgraded Their Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Revenue Forecasts By 11%
Aug 11Here's Why Ligand Pharmaceuticals (NASDAQ:LGND) Can Manage Its Debt Responsibly
Jun 27Ligand Pharmaceuticals: Moving Parts Keep Moving
Mar 29We Think Ligand Pharmaceuticals (NASDAQ:LGND) Can Manage Its Debt With Ease
Mar 17Ligand: Green Shoots And A Hidden Treasure - A Spinoff Bonus For The New Year
Dec 31Shareholder Returns
LGND | US Pharmaceuticals | US Market | |
---|---|---|---|
7D | -1.9% | -1.3% | 1.0% |
1Y | 18.7% | 19.1% | 23.6% |
Return vs Industry: LGND exceeded the US Pharmaceuticals industry which returned 19.1% over the past year.
Return vs Market: LGND underperformed the US Market which returned 23.6% over the past year.
Price Volatility
LGND volatility | |
---|---|
LGND Average Weekly Movement | 6.2% |
Pharmaceuticals Industry Average Movement | 9.7% |
Market Average Movement | 5.7% |
10% most volatile stocks in US Market | 14.8% |
10% least volatile stocks in US Market | 2.8% |
Stable Share Price: LGND has not had significant price volatility in the past 3 months.
Volatility Over Time: LGND's weekly volatility (6%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1987 | 58 | Todd Davis | www.ligand.com |
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and children aged 8 years and older with Stage 2 T1D; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression; and Veklury, an antiviral treatment for moderate or severe COVID-19.
Ligand Pharmaceuticals Incorporated Fundamentals Summary
LGND fundamental statistics | |
---|---|
Market cap | US$1.49b |
Earnings (TTM) | US$96.34m |
Revenue (TTM) | US$118.31m |
15.4x
P/E Ratio12.6x
P/S RatioIs LGND overvalued?
See Fair Value and valuation analysisEarnings & Revenue
LGND income statement (TTM) | |
---|---|
Revenue | US$118.31m |
Cost of Revenue | US$33.52m |
Gross Profit | US$84.79m |
Other Expenses | -US$11.55m |
Earnings | US$96.34m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | 5.36 |
Gross Margin | 71.67% |
Net Profit Margin | 81.43% |
Debt/Equity Ratio | 0% |
How did LGND perform over the long term?
See historical performance and comparison